Insmed Executive Makes a Multi-Million Dollar Stock Sale!

New insider activity at Insmed ( (INSM) ) has taken place on November 14, 2025.

Chief People Strategy Officer Orlov Nicole Schaeffer recently sold 30,000 shares of Insmed stock, amounting to a significant transaction valued at $5,820,060.

Recent Updates on INSM stock

Insmed’s recent financial developments have been marked by a successful Q3 earnings call, highlighting strong performances and strategic advancements. The company reported impressive sales for its newly launched drug BRINSUPRI, generating $28 million in net sales with significant physician engagement, although initial market access challenges were noted. ARIKAYCE also achieved record revenue growth, prompting an increase in future revenue guidance. Regulatory progress for brensocatib in the EU and a robust pipeline with upcoming clinical trials were also emphasized. Analysts have raised Insmed’s price targets, driven by the successful drug launches, confidence in the management team, and the company’s evolving position as a diversified, respiratory-focused growth platform. Despite these achievements, uncertainties around market access and reimbursement criteria for BRINSUPRI remain a concern.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

Insmed’s stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. While technical analysis shows strong momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh heavily. The positive sentiment from the earnings call is not factored into the overall score due to its exclusion from the weighted calculation.

To see Spark’s full report on INSM stock, click here.

More about Insmed

YTD Price Performance: 172.99%

Average Trading Volume: 2,200,790

Technical Sentiment Signal: Buy

Current Market Cap: $41.46B